SENTARA COMMUNITY PLAN (MEDICAID)

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

<u>Directions</u>: <u>The prescribing physician must sign and clearly print name (preprinted stamps not valid)</u> on this request. All other information may be filled in by office staff; <u>fax to 1-800-750-9692</u>. No additional phone calls will be necessary if all information (<u>including phone and fax #s</u>) on this form is correct. <u>If the information provided is not complete, correct, or legible, the authorization process can be delayed.</u>

Chronic GI Motility Drugs

Drug Requested: (Check box below that applies)

Preferred Medications* (must be tried and failed <u>FIRST</u>) *Need trial and failure of laxative classes								
	lubiprostone	□ Linzess®	□ Movantik®					
		Non-Preferred Med	ications					
	alosetron	□ Amitiza®	□ Ibsrela [®]					
	Lotronex [®]	□ Motegrity®	prucalopride					
	Symproic [®]	□ Viberzi [®]						
M	EMBER & PRESCRIBI	ER INFORMATION: A	authorization may be delayed if incomplete.					
Me	mber Name:							
Me	mber Sentara #:							
Pre	scriber Name:							
	scriber Signature:							
Off	ice Contact Name:							
Pho	one Number:		Fax Number:					
NP.	I #:							
D]	RUG INFORMATION:	Authorization may be delayed	d if incomplete.					
Drı	ig Name/Form/Strength:							
Dosing Schedule:			ength of Therapy:					
Dia	gnosis:	IO	ICD Code, if applicable:					
Weight (if applicable):			Date weight obtained:					

(Continued on next page)

CLINICAL CRITERIA AND DIAGNOSIS: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

Does 1	the member have any of the following diagnoses? (Check all that apply.)						
	Chronic Idiopathic Constipation (CIC)						
☐ Constipation Predominant Irritable Bowel Syndrome (IBS-C)							
	 □ Functional Constipation (FC) in pediatric patients 6 to 17 years of age (Linzess 72mcg only) □ Does the prescriber attest that other causes of constipation have been ruled out? 						
	Severe Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)						
	□ Opioid Induced Constipation in chronic NON-cancer pain (OIC)						
	Other:						
	amitiza®/ Ibsrela®/ Linzess®/ lubiprostone:						
	nember had a treatment failure on at least TWO (2) of the following classes in add red medications if non preferred medication being requested?	itior	1 to 2 c	of the	;		
•	Osmotic Laxative s (i.e., lactulose, polyethylene glycol, sorbitol); OR		Yes		No		
•	Bulk forming Laxatives (i.e., psyllium, fiber), OR		Yes		No		
•	Stimulant Laxative s (i.e., bisacodyl, senna)?		Yes		No		
	amitiza®/ lubiprostone/ Movantik®/ Symproic® (OIC only):						
Has m	nember had treatment failure on both polyethylene glycol AND lactulose in addition	n tc	2 of t	he pr	eferred		
medic	ations if non preferred medication being requested?		Yes		No		
	Alosetron/ Lotronex®/ Viberzi®:						
Has m	nember had a treatment failure on a least THREE (3) of the following classes?						
•	Bulk forming Laxatives (i.e, psyllium, fiber)		Yes		No		
•	Antispasmodic Agents (i.e, dicyclomine, hyoscyamine)		Yes		No		
•	Antidiarrheal Agents (i.e, loperamide, diphenoxylate/atropine)?		Yes		No		
□ N	Iotegrity [®] / prucalopride						
Has m	nember had a treatment failure on the following?		Yes		No		
•	≥2 preferred traditional laxative therapy (e.g., polyethylene glycol, lactulose); AN	ID					
•	≥1 preferred newer products indicated for CIC (e.g., linaclotide, lubiprostone)						

(Continued on next page)

PA GI Chronic Motility Drugs (Medicaid)

(Continued from previous page)

List pharmaceutical agents attempted and outcome:					
1					
2					
3					
MEDICAL NECESSITY: Provide clinical evidence that the PREFERRED drugs will not					

provide adequate benefit.

**Use of samples to initiate therapy does not meet step edit/ preauthorization criteria. **

Previous therapies will be verified through pharmacy paid claims or submitted chart notes.